Early Detection for Pancreatic Cancer Project

How I Serve

I search for emerging companies, technologies, disruptive technologies, innovations, start-ups and up-starts. I’ll look to match potential problems… e.g. “plastic pollution” to solutions… e.g. 3D Printer for recycled plastic waste…for potential venture capitalists, angel investors, and online funders. I’ll also highlight a variety of topics including funding success stories, the environment, housing, medical, artificial intelligence, science, aging populations, disabled populations, social entrepreneurs, philanthropy, and topical news. I’m always searching for great people innovating, inventing, and doing, great things.

I don’t endorse. Only disseminate.

The 411: Successfully Funded Project to Detect Pancreatic Cancer Early

Found on: https://experiment.com/projects/identification-of-pancreatic-cancer-specific-tumor-markers-for-early-detection?s=discover

About This Project

Pancreatic cancer is the third leading cause of cancer-related death in the US, and expected to become the second leading cause of cancer death by 20201. Pancreatic cancer is frequently not diagnosed until it has metastasized resulting in 5-year survival rate of 8%. We will identify novel tumor markers to detect pancreatic cancer at an early stage.

1: Pancreatic Cancer Action Network 2016

Ask the Scientists

JOIN THE DISCUSSION

What is the context of this research?

We have created a nontraditional method to identify novel pancreatic cancer- specific tumor markers by using pancreatic cancer patients' blood samples in order to develop a diagnostic test. This process has the potential to isolate pancreatic cancer-specific tumor markers from tissue and blood of patients diagnosed with pancreatic cancers. We believe that this process can be used to identify pancreatic cancer in its early stages. By using non-invasive, quantitative blood tests, we can validate this process and identify pancreatic cancer specific tumor markers for early detection.

What is the significance of this project?

Pancreatic cancer is frequently diagnosed in a late stage. There is only one FDA- approved tumor marker (CA19-9) for detecting pancreatic cancer. It is isolated from and specific to colon cancer cells, and is often unreliable, non-specific and not recommended by leading clinical oncology groups. Specific pancreatic cancer tumor markers are urgently need for diagnosing pancreatic cancer at early stages. Early diagnosis of pancreatic cancer will prevent recurrent or metastatic pancreatic cancer, aid therapy, and save many lives.

What are the goals of the project?

We plan to utilize our novel process and extensive experience to identify pancreatic cancer specific tumor markers, and develop a diagnostic blood test. We will measure the quantities of newly isolated specific tumor markers in >500 blood samples and cell lines. These samples will come from patients at the time of diagnosis with recurrent or metastatic pancreatic cancer. We will compare these with healthy blood samples to isolate pancreatic cancer-specific markers.